Abstract. Intranasal treatment with desglycinamide9\x=req-\ (Arg8)-vasopressin (DGAVP) 
and that these responses are disrupted in rats with hereditary hypothalamic diabetes insipidus (DI) lacking the ability to synthetize vasopressin (de Wied et al. 1975 ). The influence of vasopressin on these behavioural responses appeared to be dissociated from its action on blood pressure and water metabolism, as could be inferred from the effect of fragments of vasopressin e.g. desglycinamide9-(Arg8)-vasopressin (DGAVP) , which are practically devoid of the classic endocrine effects of vasopressin (van Ree et al. 1978; de Wied et al. 1972 de Wied et al. , 1984 .
Although a beneficial effect of vasopressin and related peptides on memory functions has been observed in humans, the sofar collected data are not consistent (Jolies 1983; Legros & Lancranjan 1984; van Ree et al. 1985) . In particular, conflict¬ ing results have been reported in patients suffer¬ ing from Korsakoffs or Alzheimer's diseases, which may be related to a more or less widespread pathologic process in the brain of these patients, probably resulting in more or less severity of cognitive disturbances. In most of these clinical trials, vasopressin or l-desamino-8-D-argininevasopressin has been administered. The inherent antidiuretic properties of these peptides could have interfered with their supposed enhancing action on memory functions. In previous studies we have found that DGAVP has effects on mem¬ ory processes in some, but not all patients (Laczi et al. 1983a,b 
Discussion
The present data confirm and extend previous findings showing a beneficial effect of DGAVP on cognitive processes (Laczi et al. 1983a,b; 
